Related Experiment Videos
Leishmania transmission-blocking vaccines: a review
1Centre for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi.
Objective:
To review information on transmission-blocking vaccine against Leishmania infections.
Data Sources:
Peer-reviewed journals and accepted manuscripts in press.
Study Selection:
Laboratory studies based on raising of immune sera against Leishmania-derived antigens using the BALB/c and hamster murine models. Testing of the immune sera for their potential to limit the transmission of cutaneous leishmaniasis in its natural vector Phlebotomus duboscqi.
Data Synthesis:
Leishmania major-derived recombinant 63 kilodalton glycoprotein (rgp63), lipophosphoglycan (LPG), whole parasite, flagella and nuclear fractions; monoclonal antibodies and sandfly gut antigens have all been tested for their candidacy as Leishmania-transmission blocking vaccines.
Conclusion:
Liposphoglycan proved to be a promising candidate for Leishmania transmission-blocking vaccine studies.